New Designer Drug Detected in Toronto Fentanyl Supply Raises Concerns

glass laboratory vials containing trace amounts of powder next to a medical testing pipette on a sterile stainless steel counter in a public health facility, wi

AI-generated illustration; not a photograph of the reported event.

  • calendar_today November 19, 2026
  • Business

Emergence of a New Designer Drug in Toronto

A newly identified opioid, believed to be part of a growing class of designer drugs, has been found in fentanyl samples in Toronto, according to Toronto’s Drug Checking Service. This substance is the sixth new drug discovered in the city's fentanyl street supply so far in 2026, highlighting the changing composition and contamination issues fueling Canada’s opioid overdose crisis.

Details of the Novel Orphine Opioid

The new drug, described as either N’-Phenethyl-5-chloro nor-orphine or N’-Phenethyl-6-chloro nor-orphine, is so novel that it doesn’t yet have a generic name. Karen McDonald, executive director of the drug checking program based at St. Michael’s Hospital, revealed that the drug was first identified in four fentanyl samples in October. The chemical is closely related to others in the orphine opioid class—a group known for their potency and prevalence in illicit markets. It has also recently been detected in samples from Vancouver.

Lack of Research Fuels Uncertainty

Little is currently known about the strength and potential effects of this newly found orphine opioid. McDonald noted, “This is a really good example of what we’re dealing with, with the unregulated fentanyl supply. It is just evolving, and the substances that are presenting are incredibly novel.” The difficulties in monitoring and identifying such substances speak to broader challenges faced by public health and drug monitoring services.

Drug Interactions Add to Risks

Dr. Cristiana Stefan, a clinical biochemist and lab director at the Centre for Addiction and Mental Health, expressed concern over how this new orphine might interact with other substances. Analysis of Toronto's fentanyl supply shows that 96 percent of samples gathered in recent studies were cut with at least one non-opioid substance—most commonly a veterinary tranquilizer or benzodiazepine, a class of depressants. Furthermore, 83 percent of samples contained multiple high-potency opioids, and over a quarter contained a combination of high-potency opioid, vet tranquilizer, and benzodiazepine.

Multi-Substance Overdose Deaths on the Rise

The Public Health Agency of Canada reports that overdose deaths involving multiple substances have increased significantly. The share of opioid or stimulant overdose deaths involving at least three substances rose from 20 percent in 2018 (491 deaths) to 42 percent in 2023 (over 1,500 deaths).

Shifting Drug Market Dynamics

Dan Werb, a substance use epidemiologist and St. Michael’s Hospital Chair in Mental Health and Substance Use Disorders, explains that the illicit opioid market has experienced drastic changes since fentanyl overtook heroin as the primary opioid, moving production from poppy fields to small-scale laboratories. Producers tailor their chemical recipes in response to both regulatory changes and user reactions, sometimes reducing potency if adverse outcomes increase.

This ongoing cycle was seen with carfentanil, an opioid about 100 times stronger than fentanyl, which was linked to 20 percent of opioid overdose deaths in Canada at its 2019 peak but declined to three percent in 2024. Werb notes that a reduction in the potency of some illicit opioids has contributed to fewer overdose fatalities since 2023. However, he warns markets remain unpredictable: “At any time, new products could be introduced. Now we’ve got orphine opioids, what people call now ultra-potent opioids.”

Monitoring and Response

The continued evolution and contamination of the street fentanyl supply pose challenges for health and drug monitoring services. As new, unstudied opioids enter the market, local services like Toronto’s Drug Checking Service track these shifts but stress the urgent need for vigilance and research.

Source: toronto.citynews.ca.

Recent Posts

Google Ads

add ads here

Hot Categories